Paraxanthine is a defined chemical compound with the molecular formula C7H8N4O2, a molecular weight of approximately 180.16 g/mol, and CAS number 611-59-6. Scientific databases also identify it as 1,7-dimethylxanthine. These identifiers matter in procurement because a commercial ingredient should be confirmed by identity testing — not merely by a trade name or a marketing description.
In everyday biology, paraxanthine is best known as a caffeine metabolite. After caffeine is absorbed, liver enzymes — especially CYP1A2 — convert much of it into paraxanthine. That metabolic relationship, however, does not automatically establish that every manufactured paraxanthine ingredient is suitable for every food or supplement use. Commercial identity, manufacturing controls, impurity limits, intended use, and regulatory documentation remain source-specific.
Caffeine and paraxanthine are related methylxanthines, but they are not the same molecule. Caffeine is the starting compound consumed in coffee, tea, many energy drinks, and supplements; paraxanthine is its major human metabolite. Direct paraxanthine supplies that downstream molecule without requiring the initial conversion from caffeine.
For product developers, the most defensible position is that paraxanthine offers a differentiated methylxanthine story with a growing research base. Head-to-head superiority over caffeine should be claimed only when a suitable study supports the exact endpoint, dose, population, and ingredient being marketed.
| Study | What it reported | How to interpret it |
| Yoo et al., 2021 | A randomized, double-blind, placebo-controlled crossover trial reported changes in selected measures of cognition, short-term memory, attention, and reaction time after an acute 200 mg dose. | A small acute study can identify signals; it cannot establish long-term effects or a universal response. |
| Xing et al., 2021 | Twelve healthy adults received placebo or 50, 100, and 200 mg in a crossover design, acutely and for seven days. Effects were more consistent at 100 and 200 mg for some cognitive outcomes. | The sample and duration were limited, and sponsor relationships were disclosed. The studied doses are research conditions, not automatic formulation recommendations. |
| Diedhiou et al., 2026 | In 14 male university-level rowers, 200 mg paraxanthine alone did not show clear standalone improvement in 2,000 m rowing versus placebo; the combined caffeine-plus-paraxanthine condition performed best. | Useful newer human data, but small, male-only, and based partly on subjective sleep measures. It argues against claiming proven standalone ergogenic superiority. |
A 2023 toxicology program evaluated paraxanthine in several in vitro genetic-toxicity assays and in acute, 14-day, and 90-day oral studies in rats. In the 90-day rat study, the reported no-observed-adverse-effect level (NOAEL) was 185 mg/kg body weight per day for the tested paraxanthine material.
In the United States, a GRAS conclusion is tied to a specific substance, manufacturing process, specifications, intended conditions of use, and supporting dossier. A supplier statement such as self-GRAS should not be presented as “FDA approved.”
Paraxanthine gives product teams a new way to frame energy and focus without simply adding another caffeine source. Format feasibility still requires product-level work: beverage teams should assess solubility, pH, taste, processing conditions, compatibility, and finished-product stability; powder and capsule teams should evaluate flow, blend uniformity, excipient interactions, serving precision, and packaging.
|
According to Youyou Biotechnology’s current product specification, PRAXPULSE™ Paraxanthine powder is identified as CAS 611-59-6, supplied as a light-yellow powder, and specified at no less than 99.0% by HPLC.
|
Is paraxanthine the same as caffeine?
No. Paraxanthine is a distinct methylxanthine and the predominant metabolite formed from caffeine in humans.
Is paraxanthine naturally produced in the body?
Yes, the body forms paraxanthine when it metabolizes caffeine. That fact does not replace source-specific evaluation of a commercial ingredient.
Is paraxanthine safe?
Available short-term human and preclinical studies provide useful evidence, but the long-term human evidence base is still limited. Safety and regulatory suitability must be assessed for the exact material, dose, population, and intended use.
Does paraxanthine cause no jitters or no crash?
No universal absence-of-side-effects claim is supported. Individual response varies.
What paraxanthine dosage has been studied?
Human studies have evaluated doses including 50, 100, and 200 mg, but study doses are not universal formulation recommendations.
What should a bulk buyer request?
At minimum: specification, COA, identity and assay methods, impurity and contaminant controls, stability data, source-specific regulatory support, certifications, MOQ, lead time, and sample information.
[1]National Center for Biotechnology Information. PubChem Compound Summary for CID 4687, Paraxanthine.
[3]Xing D, et al. Dose-Response of Paraxanthine on Cognitive Function... Nutrients. 2021;13(12):4478.
[5]Szlapinski SK, et al. Paraxanthine safety and comparison to caffeine. Front Toxicol. 2023;5:1117729.
[7]U.S. Food and Drug Administration. GRAS Notice Inventory.
[8]Youyou Biotechnology. PRAXPULSE™ Paraxanthine product page.
